The Factor Assays Market is estimated to grow at a CAGR of 6.4% over the forecast period of 2023-2028 and garner a market size equivalent to $169.3 million by 2028. Factor assays are able to identify specific factor deficiencies that lead to rare issues such as blood clotting disorders. Factor assay-based tests are performed after mixing studies and if a deficiency of one or more coagulation factors is suspected. The test involves performing a Prolonged Activated Partial Thromboplastin Time Test (APTT) or PT. Some of the common condition known as high-molecular-weight kininogen (HMWK) that participates in the initiation of blood coagulation is hampered. In 2022, North America held a dominant market share of 37% owing to a higher disease prevalence and the supporting facilities to aid the developing cases.

Factor Assays Market Drivers

The Global Rise in Cardiovascular Cases with Underlying Conditions:

Cardiovascular illnesses and blood disorders have been on a rampant increase in the population. As per WHO, nearly 17-19 million people annually die due to cardiovascular diseases. Various studies have shown a high correlation between the incidence of coagulation deficiencies and cardiovascular diseases. Factor assay technology rightly aids in the timely detection of any coagulating factor deficiency, thereby helping in saving lives. The clots formed within the body can result in conditions such as stroke, heart attacks, severe leg pain and others.

For More Queries About "Factor Assays Market" @

Innovation and Soaring Expenditure in the Healthcare Industry:

An increase in the proliferation of innovation in various healthcare models has been seen in the last decade, especially in various hospitals, diagnostics testing centers, laboratory testing facilities and others through which the revenue of factor assays has benefited. In countries such as India, various online healthcare platforms are facilitating the usage of taking blood tests, which rightly aids in the direction of coagulation testing. Further, the U.S. FDA has asked for a budget of $8.4 billion to aid investments in critical public health modernization, core food safety, medical product safety programs and other vital public health infrastructure.

Clinical Research & Product Launch

In November 2022, CUREUS published a research article stating that acquired factor D deficiency strongly correlates with various viral respiratory tract infections. Owing to the high number of COVID-19 cases worldwide, the acquired forms of deficiencies might turn high. In May 2022, Precision Biologics launched the CRYOchem Chromogenic Factor IX assay in Canada, the EU, the United Kingdom, Australia and New Zealand.

Major Players in the Market

The major players in the Factor Assays market include Abbott, Becton Dickinson, Beckman Coulter, Grifols, Roche, Thermo Fisher Scientific, Accriva, Helena Biosciences, Merck and Technoclone.

To request for a quote, provide your details in the below link:

Media Contact:

Mr. Venkat Reddy
Sales Manager
Contact Sales: +1-970-236-3677

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.